Acc Consensus On New Diabetes Drugs To Reduce Cv Outcomes | Latest News RSS feed

Acc Consensus On New Diabetes Drugs To Reduce Cv Outcomes - Latest News

2018 American College of Cardiology ECDP Encourages Collaboration Among Specialists and PCPs

The decision pathway appeared in the cardiovascular brief only a few months ago. The American Diabetes Association has been revising these guidelines with the ACC since ... by which these drugs reduce ... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

The 2018 ACC Expert Consensus statement emphasizes the need for a collaborative treatment approach by healthcare providers to reduce cardiovascular ... care and outcomes of people with type 2 diabetes ... read more

Amarin: A Rebuttal To Omega-3 Fans

This astounding prediction comes just after Amarin's REDUCE-IT trial was deemed "best cardiovascular news ... IDF Diabetes Atlas, EM Consulte, WHO, Eurostat, Nature, Statcan, & ACC; *Note: Middle ... read more

Looking for another news?

New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting

Following a review of the latest evidence —including a range of recent trials of drug and lifestyle interventions—the European Association for the Study of Diabetes ... They add: "New questions arise ... read more

Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events

The approval of this new indication offers hope for patients who continue to struggle with achieving lower ... in the Cardiovascular Outcomes Trial (>5% of patients treated with Repatha and occurring ... read more

New class of drugs may reduce severe heart failure, prolong life in diabetics

Diabetes ... rate A new study, presented at the American College of Cardiology (ACC) scientific sessions in Washington DC last week, showed that a relatively new class of drugs called sodium glucose c... read more

UPMC Health Plan and Boehringer Ingelheim Announce Innovative, Value-Based Agreement

Cardiovascular disease is ... clinical experts to promote optimal diabetes management, better medication adherence and to support healthier lifestyles - all with the goal of better health outcomes and ... read more

Almost Half of Americans Have High Blood Pressure Under New Guidelines

In the first change to blood pressure guidelines in 14 years, the American Heart Association and the American College of Cardiology say that the threshold for high blood pressure should be lower. Unde... read more

Certain SGLT2 inhibitors, GLP-1 RAs for T2DM also cut CV risk

The authors note that specific medications in these classes can reduce ... CV risk in patients not treated with metformin. "We anticipate that the algorithms proposed here will change as new evidence ... read more

Have Diabetes? Why You Need to Know Your Blood Pressure Numbers

“So, not only are both of those conditions related to adverse cardiovascular events, but they often occur in tandem in people with diabetes.” Now, a recent study published in the Journal of the Americ... read more

Novo Nordisk: Pick Up This Diabetes Leader In 2018

New ... ability to reduce cardiovascular events in type 2 diabetes patients. Already approved in USA and Europe, the drug awaits regulatory decision in Japan in 2018. By mid of 2018, Novo Nordisk now ... read more

Boehringer Ingelheim, Lilly partner with DCRI to advance multidisciplinary care for people with type 2 diabetes & cardiovascular disease

The research programme, COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs ... and the American College of Cardiology (ACC) Expert Consensus Dec... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us